Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3001–3024 of 3,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension and Coronary Artery Disease
Interventions: Celecoxib, placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 50 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 2
States / cities: Gainesville, Florida • Houston, Texas

Conditions: Hypertension, Insulin Resistance, Dyslipidemia
Interventions: Telmisartan; Drug
Lead sponsor: Stanford University; Other
Eligibility: 10 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Stanford, California

Conditions: Coronary Heart Disease, Stroke, Hyperlipidemia, Hypertension
Interventions: Enhance health lifestyle changes and medication compliance; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 35 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pulmonary Arterial Hypertension
Interventions: UT-15C (treprostinil diolamine); Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 38
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more

Conditions: Blood Pressure, Endothelial Dysfunction, Hypertension
Interventions: Inspiratory muscle strength training, Brisk walking; Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 50 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Glaucoma
Interventions: Use of ologen Collagen Matrix in trabeculectomy (ologen), Use of Mitomycin-C (MMC) in trabeculectomy; Device · Drug
Lead sponsor: Aeon Astron Europe B.V.; Industry
Eligibility: 30 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 8
States / cities: Rogers, Arkansas • Chicago, Illinois • Newark, New Jersey + 4 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Inhaled Nitric Oxide; Drug
Lead sponsor: Geno LLC; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 2
States / cities: Birmingham, Alabama • Pittsburgh, Pennsylvania

Conditions: Hydrocephalus, Idiopathic Intracranial Hypertension, Pseudotumor Cerebri
Interventions: Tympanic membrane displacement (TMD), DPOAE; Device
Lead sponsor: LifeBridge Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: METABOLIC SYNDROME, HYPERTENSION, PRE-HYPERTENSION
Interventions: valsartan plus hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 507 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: Febuxostat, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 45
States / cities: Foley, Alabama • Buena Park, California • Carmichael, California + 42 more

Conditions: Liver Diseases, Portal Hypertension
Interventions: SHAPE measurement (Sonazoid ultrasoud contrast agent), SHAPE measurement (Definity ultrasoud contrast agent); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension, Systolic, Cerebrovascular Disease
Interventions: Anti-hypertensive therapy to SBP 130 mm Hg, Anti-hypertensive therapy to SBP 145 mm Hg; Other
Lead sponsor: UConn Health; Other
Eligibility: 75 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Hypertension, Hyperlipidemias
Interventions: Atorvastatin, placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo); Drug · Other
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 5
States / cities: Mission Hills, California • Morrow, Georgia • Ann Arbor, Michigan + 2 more

Conditions: Stroke, Hypertension
Interventions: Home BP Telemonitoring (HBPTM), Nurse Case Management (NCM); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Open-Angle
Interventions: Not listed
Lead sponsor: Glaukos Corporation; Industry
Eligibility: Not listed
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 24
States / cities: Glendale, Arizona • Fayetteville, Arkansas • Santa Rosa, California + 20 more

Conditions: Coronary Artery Disease, Hypertension, Hyperlipidemias, Peripheral Vascular Diseases, Cerebral Arterial Diseases
Interventions: Goodbelly, Placebo; Dietary Supplement
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 21 Years to 89 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Open Angle Glaucoma (OAG)
Interventions: VisiPlate Glaucoma Implant; Device
Lead sponsor: Avisi Technologies Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 12
States / cities: Glendale, Arizona • Los Angeles, California • Petaluma, California + 7 more

Conditions: GDM, Preterm Preeclampsia, Preeclampsia, Fetal Growth Restriction (FGR), Pregnancy Complications
Interventions: None (this is an observational study with no intervention); Other
Lead sponsor: Medicines360; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 5,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Bridgeport, Connecticut • New Haven, Connecticut • Baton Rouge, Louisiana + 2 more

Conditions: Chronic Kidney Disease, Hypertension, Diabetes
Interventions: Exercise training; Behavioral
Lead sponsor: Springfield College; Other
Eligibility: 35 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Overweight, Obesity, Diabetes, Hypertension
Interventions: Tele-health Home Monitoring, TrestleTree Telephone Coaching, Tele-health Home Monitoring Plus Trestle Telephone Coaching; Device · Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Baton Rouge, Louisiana • Houma, Louisiana • Lake Charles, Louisiana

Conditions: Surgery
Interventions: Esophageal pressure measurement guided ventilation; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diastolic Dysfunction, Hypertension
Interventions: Valsartan; Drug
Lead sponsor: Novartis; Industry
Eligibility: 45 Years and older
Enrollment: 317 participants
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

Effect of Celecoxib on Markers of Vascular Inflammation

Treatment of Insulin Resistance in Hypertensive, Obese Adolescents

Heart Disease on the Mend

An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Novel Time-efficient Inspiratory Muscle Strength Training for Lowering Systolic Blood Pressure

Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Glaucoma Filtering Surgery

Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide

Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement

A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome

Effect of Febuxostat on Blood Pressure

Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal

Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People

Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

Practice-Based Trial of Home BP Telemonitoring Among Minority Stroke Survivors

iStent Inject Trabecular Micro-Bypass System Continuation Post-Approval Study

Acute Probiotic Supplementation and Endothelial Function

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma

Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study

Aerobic Training and Arterial Stiffness in Chronic Kidney Disease (CKD) Patients

Weight Loss in Chronic Disease Patient Population

Esophageal Balloon Measurements to Better Characterize Thoraco-abdominal Interrelationship Mechanics.

To Find Out Whether Valsartan With or Without Other Blood Pressure Medications Would Improve the Ability of the Heart to Fill and Empty, and the Ability of the Heart Muscle to Relax Adequately in People With High Blood Pressure.